MX2017003303A - Neutralizacion de vias inhibidoras en linfocitos. - Google Patents

Neutralizacion de vias inhibidoras en linfocitos.

Info

Publication number
MX2017003303A
MX2017003303A MX2017003303A MX2017003303A MX2017003303A MX 2017003303 A MX2017003303 A MX 2017003303A MX 2017003303 A MX2017003303 A MX 2017003303A MX 2017003303 A MX2017003303 A MX 2017003303A MX 2017003303 A MX2017003303 A MX 2017003303A
Authority
MX
Mexico
Prior art keywords
lymphocytes
neutralization
inhibitory pathways
compounds
nkg2a
Prior art date
Application number
MX2017003303A
Other languages
English (en)
Inventor
Andre Pascale
Blery Mathieu
Paturel Carine
Wagtmann Nicolaï
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of MX2017003303A publication Critical patent/MX2017003303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona a métodos para el tratamiento, prevención y diagnóstico de enfermedades, utilizando compuestos que se unen e inhiben específicamente NKG2A de humano en combinación con compuestos que se unen e inhiben PD-1 de humano. La invención además se relaciona a los ensayos para identificar linfocitos NK infiltrantes de tumor NKG2A+PD1+ y/o linfocitos T CD8.
MX2017003303A 2014-09-16 2015-09-15 Neutralizacion de vias inhibidoras en linfocitos. MX2017003303A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462050948P 2014-09-16 2014-09-16
US201462083929P 2014-11-25 2014-11-25
US201462093141P 2014-12-17 2014-12-17
PCT/EP2015/071069 WO2016041945A1 (en) 2014-09-16 2015-09-15 Neutralization of inhibitory pathways in lymphocytes

Publications (1)

Publication Number Publication Date
MX2017003303A true MX2017003303A (es) 2017-08-04

Family

ID=54147180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003303A MX2017003303A (es) 2014-09-16 2015-09-15 Neutralizacion de vias inhibidoras en linfocitos.

Country Status (24)

Country Link
US (3) US10711063B2 (es)
EP (3) EP3193931B1 (es)
JP (2) JP6767362B2 (es)
KR (2) KR102543739B1 (es)
CN (2) CN113929782B (es)
AU (1) AU2015316991B2 (es)
BR (1) BR112017005178A2 (es)
CA (1) CA2957491A1 (es)
CY (1) CY1123827T1 (es)
DK (1) DK3193931T3 (es)
ES (1) ES2825576T3 (es)
HR (1) HRP20201656T1 (es)
HU (1) HUE051193T2 (es)
IL (1) IL250587B (es)
LT (1) LT3193931T (es)
MX (1) MX2017003303A (es)
PL (1) PL3193931T3 (es)
PT (1) PT3193931T (es)
RS (1) RS60935B1 (es)
RU (1) RU2734771C2 (es)
SG (2) SG10202008228XA (es)
SI (1) SI3193931T1 (es)
WO (1) WO2016041945A1 (es)
ZA (1) ZA201702642B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
BR112013032217B1 (pt) 2011-06-17 2021-01-19 Novo Nordisk A/S uso de um anticorpo anti-nkg2a
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
PL3193931T3 (pl) 2014-09-16 2021-03-08 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
CN107850596B (zh) 2015-07-24 2020-12-04 先天制药公司 用于检测组织浸润nk细胞的方法
EP3868787A1 (en) * 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
IL264104B2 (en) 2016-07-07 2024-08-01 Iovance Biotherapeutics Inc PD-L1 binding proteins and methods of using them
DE102017001875A1 (de) * 2017-02-27 2018-08-30 Wolfgang Würfel Medikament zur Malignombehandlung
US11447545B2 (en) * 2017-07-10 2022-09-20 Innate Pharma Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer
EP3625263A4 (en) 2017-10-27 2021-05-05 New York University ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
US11795222B2 (en) 2018-03-13 2023-10-24 Innate Pharma Treatment of head and neck cancer
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
AU2019270277A1 (en) * 2018-05-15 2021-01-07 Innate Pharma Treatment of cancer
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
EP3818082A1 (en) * 2018-07-04 2021-05-12 F. Hoffmann-La Roche AG Novel bispecific agonistic 4-1bb antigen binding molecules
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
KR20220016156A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
MX2023007650A (es) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Metodos de tratamiento de tumores.
JP2024503265A (ja) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー 抗体組成物およびその使用の方法
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
CN114214430A (zh) * 2021-12-20 2022-03-22 安徽中盛溯源生物科技有限公司 Nkg2a在检测小鼠人源肿瘤模型中人nk细胞中的应用
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
BR0311471A (pt) 2002-05-30 2007-04-27 Macrogenics Inc anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
CA2508660C (en) * 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
PT1648507T (pt) * 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
EP1831258B2 (en) * 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
CN101107269B (zh) * 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
EP2038306B1 (en) 2006-06-30 2014-12-03 Novo Nordisk A/S Anti-nkg2a antibodies and uses thereof
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
JP5774312B2 (ja) 2008-01-24 2015-09-09 ノボ・ノルデイスク・エー／エス ヒト化抗ヒトｎｋｇ２ａモノクローナル抗体
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) * 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
SI2342226T1 (sl) * 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
CA2992770A1 (en) 2009-11-24 2011-06-03 Medimmune Limited Targeted binding agents against b7-h1
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
BR112013032217B1 (pt) 2011-06-17 2021-01-19 Novo Nordisk A/S uso de um anticorpo anti-nkg2a
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
ES2746805T3 (es) 2013-12-12 2020-03-06 Shanghai hengrui pharmaceutical co ltd Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
CA2959318A1 (en) 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
PL3193931T3 (pl) 2014-09-16 2021-03-08 Innate Pharma Neutralizacja szlaków inhibitorowych w limfocytach
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
EP3868787A1 (en) 2016-01-21 2021-08-25 Innate Pharma Neutralization of inhibitory pathways in lymphocytes

Also Published As

Publication number Publication date
CN107001466B (zh) 2021-10-26
AU2015316991B2 (en) 2021-04-01
US20230235060A1 (en) 2023-07-27
RU2017105118A3 (es) 2019-04-25
WO2016041945A1 (en) 2016-03-24
RU2017105118A (ru) 2018-10-17
ZA201702642B (en) 2018-08-29
IL250587A0 (en) 2017-04-30
AU2015316991A1 (en) 2017-03-09
KR20170067732A (ko) 2017-06-16
KR102543739B1 (ko) 2023-06-16
EP3193931A1 (en) 2017-07-26
CY1123827T1 (el) 2022-03-24
LT3193931T (lt) 2020-11-10
HRP20201656T1 (hr) 2021-03-05
DK3193931T3 (da) 2020-10-19
US20170291947A1 (en) 2017-10-12
CN113929782A (zh) 2022-01-14
CN113929782B (zh) 2024-06-21
IL250587B (en) 2021-12-01
US11572410B2 (en) 2023-02-07
CA2957491A1 (en) 2016-03-24
JP2020147572A (ja) 2020-09-17
PT3193931T (pt) 2020-10-23
PL3193931T3 (pl) 2021-03-08
NZ729207A (en) 2021-08-27
RU2734771C2 (ru) 2020-10-23
ES2825576T3 (es) 2021-05-17
SI3193931T1 (sl) 2020-12-31
BR112017005178A2 (pt) 2018-03-06
SG10202008228XA (en) 2020-09-29
JP6767362B2 (ja) 2020-10-14
HUE051193T2 (hu) 2021-03-01
SG11201701340RA (en) 2017-03-30
CN107001466A (zh) 2017-08-01
JP2017530119A (ja) 2017-10-12
KR20230088521A (ko) 2023-06-19
EP4368205A1 (en) 2024-05-15
US20200332008A1 (en) 2020-10-22
RS60935B1 (sr) 2020-11-30
US10711063B2 (en) 2020-07-14
EP3799885A1 (en) 2021-04-07
EP3193931B1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
MX2017003303A (es) Neutralizacion de vias inhibidoras en linfocitos.
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
PH12017500803A1 (en) Anti-pd-1 antibodies
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MX2020010530A (es) Anticuerpos humanizados contra cd269 (bcma).
WO2016077397A3 (en) Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
MY190324A (en) Anti-pd-1 antibodies and compositions
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
SG10201913538VA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
MX2016009616A (es) Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
MD20170032A2 (ro) Anticorpi anti-TIGIT
MD20150100A2 (ro) Virusurile bolii de Newcastle şi utilizarea acestora
WO2015185875A9 (fr) Anticorps dirigé contre la galectine 9 et inhibiteur de l'activité suppressive des lymphocytes t régulateurs
GEP20217317B (en) Combination therapy for the treatment of cancer
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017006015A (es) Composiciones para usar en el tratamiento de cancer renal.
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
MX2015011518A (es) Agentes de enlace de met y usos de los mismos.
EP3229793A4 (en) Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease
SG10201807059QA (en) Agents for influenza neutralization
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
PH12018502242A1 (en) Imidazolone compounds as human neutrophil elastase inhibitors
PH12016501838A1 (en) Compounds and their methods of use
IL248421A0 (en) Use of ctla4 compounds to achieve drug-free withdrawal in subjects with early RA